{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:41:21Z","timestamp":1793047281715,"version":"4.5.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"Importance<\/jats:title>Autoimmune skin diseases (ASDs) and cancer both involve immune system dysregulation, with ASDs characterized by heightened immune activity, and cancer associated with immune evasion; however, their impact on cancer prognosis remains unclear.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the association of ASDs with cancer prognosis and survival outcomes after antineoplastic treatment in patients with cancer.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This population-based cohort study used data from Taiwan\u2019s Nationwide Cancer Registry and National Health Insurance Database to evaluate survival outcomes in patients with cancer who received antineoplastic treatment (ie, chemotherapy, targeted therapy, or immunotherapy) between January 1, 2019, and June 30, 2021. Data were analyzed from July 2023 to April 2025.<\/jats:p><\/jats:sec>Exposures<\/jats:title>ASDs, including alopecia areata, Sj\u00f6gren syndrome, vitiligo, cutaneous lupus erythematosus, psoriasis, lichen planus, autoimmune bullous diseases, systemic sclerosis, morphea, hidradenitis, and dermatomyositis.<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>All-cause mortality and cancer-specific mortality were assessed during the follow-up period. To account for potential confounding, both inverse probability of treatment weighting (IPTW) and propensity score matching strategies were applied. Cox proportional hazards regression models were applied to estimate hazard ratios (HRs) for all-cause mortality, while the Fine-Gray hazard model was used to estimate subdistribution HRs (SHRs) for cancer-specific mortality, with noncancer-related deaths considered as competing events.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 197 895 patients included in the analysis, 26 008 were in the ASD group (mean [SD] age, 64.0 [13.3] years; 14 969 female [57.6%]) and 171 887 were in the non-ASD group (mean [SD] age, 62.8 [13.0] years; 80 525 female [46.9%]). Patients with ASDs had significantly better survival outcomes than those without ASDs, with an IPTW-adjusted HR of 0.94 (95% CI, 0.92-0.96) for all-cause mortality and an SHR of 0.94 (95% CI, 0.92-0.96) for cancer-specific mortality. These associations remained consistent in propensity score\u2013matched analyses. Among ASD subtypes, alopecia areata and Sj\u00f6gren syndrome were consistently associated with lower mortality risk.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This population-based cohort study found that patients with ASDs had significantly better cancer survival outcomes than those without ASDs. This finding suggests that there is a potential immunological association between ASDs and cancer prognoses, highlighting the need for further investigation into the underlying mechanisms and the implications for oncologic management.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.1949","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:00:33Z","timestamp":1751454033000},"page":"840","source":"Crossref","is-referenced-by-count":3,"title":["Autoimmune Skin Diseases and Survival Outcomes After Antineoplastic Treatment in Patients With Cancer"],"prefix":"10.1001","volume":"161","author":[{"given":"Sheng-Yin","family":"To","sequence":"first","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Public Health, National Defense Medical Center, Taipei, Taiwan"},{"name":"Department of Pharmacy, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Hao","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsien","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Fan","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Public Health, National Defense Medical Center, Taipei, Taiwan"},{"name":"Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Wen","family":"Yang","sequence":"additional","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Public Health, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Liang","family":"Wen","sequence":"additional","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Public Health, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ting","family":"Kao","sequence":"additional","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"},{"name":"Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"doi250029r1","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2741\/4847","article-title":"Epigenetic alterations in cancer.","volume":"25","author":"Ilango","year":"2020","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"7","key":"doi250029r2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.trecan.2020.02.003","article-title":"Cancer epigenetics, tumor immunity, and immunotherapy.","volume":"6","author":"Cao","year":"2020","journal-title":"Trends Cancer"},{"issue":"1","key":"doi250029r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer immunoediting from immune surveillance to immune escape.","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology"},{"issue":"10334","key":"doi250029r4","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(22)00242-2","article-title":"Management of common clinical problems experienced by survivors of cancer.","volume":"399","author":"Emery","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"doi250029r5","doi-asserted-by":"publisher","first-page":"e1288","DOI":"10.1016\/S2214-109X(18)30411-X","article-title":"Effect on longevity of one-third reduction in premature mortality from non-communicable diseases by 2030: a global analysis of the Sustainable Development Goal health target.","volume":"6","author":"Cao","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"10","key":"doi250029r6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","article-title":"Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070.","volume":"18","author":"Soerjomataram","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"doi250029r7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2019.01.001","article-title":"Emerging role of immune cell network in autoimmune skin disorders: An update on pemphigus, vitiligo and psoriasis.","volume":"45","author":"Das","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"doi250029r8","first-page":"S1","article-title":"Mechanisms of immune-mediated skin diseases: an overview.","volume":"24","author":"Beissert","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"doi250029r9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imm.12814","article-title":"T helper type 1 polarizing ?d T cells and scavenger receptors contribute to the pathogenesis of pemphigus vulgaris.","volume":"153","author":"Das","year":"2018","journal-title":"Immunology"},{"issue":"1","key":"doi250029r10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/jid.2008.194","article-title":"Psoriasis is characterized by accumulation of immunostimulatory and Th1\/Th17 cell-polarizing myeloid dendritic cells.","volume":"129","author":"Zaba","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi250029r11","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/odi.14142","article-title":"Immune mechanisms in oral lichen planus.","volume":"29","author":"El-Howati","year":"2023","journal-title":"Oral Dis"},{"key":"doi250029r12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.883375","article-title":"Th2 to Th1 transition is required for induction of skin lesions in an inducible and recurrent murine model of cutaneous lupus-like inflammation.","volume":"13","author":"Haddadi","year":"2022","journal-title":"Front Immunol"},{"key":"doi250029r13","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"6","key":"doi250029r14","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S2468-2667(24)00026-4","article-title":"Estimating the burden of vitiligo: a systematic review and modelling study.","volume":"9","author":"Akl","year":"2024","journal-title":"Lancet Public Health"},{"issue":"4","key":"doi250029r15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00403-014-1531-1","article-title":"Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid.","volume":"307","author":"Alpsoy","year":"2015","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"doi250029r16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi250029r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103084","article-title":"Primary Sj\u00f6gren\u2019s syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis.","volume":"21","author":"Zhong","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"8","key":"doi250029r18","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s00432-020-03245-3","article-title":"Cancer risks in patients with vitiligo: a Mendelian randomization study.","volume":"146","author":"Wen","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"doi250029r19","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/cam4.1448","article-title":"Cancer risk in patients with alopecia areata: a nationwide population-based matched cohort study.","volume":"7","author":"Chen","year":"2018","journal-title":"Cancer Med"},{"issue":"2","key":"doi250029r20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer.","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi250029r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.101472","article-title":"The relationships between cancer and autoimmune rheumatic diseases.","volume":"34","author":"Cappelli","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"doi250029r22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1053\/j.seminoncol.2015.05.007","article-title":"Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy.","volume":"42","author":"Wargo","year":"2015","journal-title":"Semin Oncol"},{"issue":"1","key":"doi250029r23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors.","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"doi250029r24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan\u2019s National Health Insurance Research Database: past and future.","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"5","key":"doi250029r25","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jfma.2019.01.012","article-title":"Taiwan\u2019s Nationwide Cancer Registry System of 40 years: past, present, and future.","volume":"118","author":"Chiang","year":"2019","journal-title":"J Formos Med Assoc"},{"issue":"28","key":"doi250029r26","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"1","key":"doi250029r27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research.","volume":"15","author":"Chesnaye","year":"2021","journal-title":"Clin Kidney J"},{"key":"doi250029r28","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"doi250029r29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/1094428112447816","article-title":"Using the propensity score method to estimate causal effects: a review and practical guide.","volume":"16","author":"Li","year":"2013","journal-title":"Organ Res Methods"},{"issue":"6","key":"doi250029r30","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jclinepi.2012.09.017","article-title":"A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions.","volume":"66","author":"Latouche","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"doi250029r31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s40471-020-00243-4","article-title":"A selective review of negative control methods in epidemiology.","volume":"7","author":"Shi","year":"2020","journal-title":"Curr Epidemiol Rep"},{"issue":"5","key":"doi250029r32","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","article-title":"The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients.","volume":"113","author":"Austin","year":"1999","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi250029r33","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12441","article-title":"Anti-cancer therapy with TNFa and IFN?: a comprehensive review.","volume":"51","author":"Shen","year":"2018","journal-title":"Cell Prolif"},{"issue":"9","key":"doi250029r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100375","article-title":"Comparing survival in patients with lung cancer with and without a history of common autoimmune disease.","volume":"3","author":"Dedousis","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"1","key":"doi250029r35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00005-017-0477-3","article-title":"Skin immunity.","volume":"66","author":"Matejuk","year":"2018","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"7","key":"doi250029r36","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.joms.2020.01.032","article-title":"Oral lichen planus-associated oral cavity squamous cell carcinoma is associated with improved survival and increased risk of recurrence.","volume":"78","author":"Best","year":"2020","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"doi250029r37","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1177\/0961203321990106","article-title":"Increased cancer risk in patients with cutaneous lupus erythematosus and systemic lupus erythematosus compared with the general population: a Danish nationwide cohort study.","volume":"30","author":"Westermann","year":"2021","journal-title":"Lupus"},{"issue":"6","key":"doi250029r38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study.","volume":"326","author":"Sigurgeirsson","year":"1992","journal-title":"N Engl J Med"},{"issue":"6","key":"doi250029r39","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.autrev.2018.01.010","article-title":"Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors.","volume":"17","author":"Tocut","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"11","key":"doi250029r40","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"doi250029r41","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41571-021-00508-x","article-title":"Beneficial autoimmunity improves cancer prognosis.","volume":"18","author":"Zitvogel","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"doi250029r42","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3390\/curroncol30020143","article-title":"Harnessing real-world evidence to advance cancer research.","volume":"30","author":"Tang","year":"2023","journal-title":"Curr Oncol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2835831\/jamadermatology_to_2025_oi_250029_1755630705.03071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T15:00:40Z","timestamp":1755702040000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2835831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.1949","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}